CCNE1 Knockout Jurkat Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T-lymphocyte leukemia line, designed for loss-of-function analysis of the CCNE1 gene. This polyclonal model retains cellular heterogeneity while enabling robust investigation of Cyclin E1-dependent signaling and cell cycle control, making it suitable for a broad range of functional studies without clonal selection.
The Jurkat cell line, originally established from a patient with acute T-cell leukemia, is a widely used model for T-cell biology, apoptosis, and oncogenic signaling. Its malignant origin offers a disease-relevant context for examining cell cycle dysregulation in T-cell acute lymphoblastic leukemia (T-ALL), where aberrant proliferation is a hallmark. These cells are particularly valuable for studying the molecular mechanisms driving leukemia maintenance and therapeutic response.
CCNE1 encodes Cyclin E1, the regulatory subunit of cyclin-dependent kinase 2 (CDK2). The Cyclin E1/CDK2 complex phosphorylates the retinoblastoma protein (RB), releasing E2F transcription factors to drive expression of S-phase genes such as NPAT, CDC6, and components of the MCM complex, thereby promoting the G1/S transition. CCNE1 expression is transcriptionally activated by E2F1 and MYC, and is modulated by upstream signals including PI3K/AKT and MAPK pathways. Protein stability is tightly controlled by the SKP2/FBXW7/CUL1 ubiquitin ligase system and inhibited by CDK inhibitors CDKN1A (p21) and CDKN1B (p27).
In the Jurkat T-ALL background, CCNE1 dysregulation contributes to unscheduled DNA replication, genomic instability, and oncogenic progression. Disruption of CCNE1 in this context allows researchers to assess oncogene addiction and the reliance of leukemia cells on Cyclin E1-mediated cell cycle progression, as well as to explore the consequences of impaired CDK2 activity in a malignant T-cell environment. This makes the knockout model particularly relevant for studying the RB tumor suppressor pathway and its crosstalk with oncogenic drivers.
These polyclonal knockout cells are ideally suited for cell cycle profiling by flow cytometry, immunoblot analysis of Cyclin E1, phospho-RB, and CDK2, and RT-qPCR quantification of E2F target transcripts. Further applications include high-throughput CDK inhibitor screening, drug sensitivity assays to evaluate resistance mechanisms, and functional dissection of CCNE1 in leukemia maintenance. For further technical support or custom requests, contact Ascent Research.
